# US Companion Diagnostic Market

> US Companion Diagnostic Market Research Report: Size, Share, Trend Analysis By Product & Service (Assays, Kits, Reagents, Software, Services), By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry, Others), By Indication (Cancer, Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, Others) and By End Users (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, Laboratories, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.5%
- **2024:** $ 1,500 Million
- **2025:** $ 1,597.5 Million
- **2035:** $ 3,000 Million
- **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Illumina (US), Qiagen (DE), Myriad Genetics (US), Hologic (US), BioMérieux (FR)

**Report ID:** MRFR/MED/13122-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-companion-diagnostic-market-14649

---

## Market Summary

## **US Companion Diagnostic Market Overview**

As per MRFR analysis, the US Companion Diagnostic Market Size was estimated at 7.28 (USD Billion) in 2023. The US Companion Diagnostic Market Industry is expected to grow from 9.01(USD Billion) in 2024 to 60.85 (USD Billion) by 2035. The US Companion Diagnostic Market CAGR (growth rate) is expected to be around 18.962% during the forecast period (2025 - 2035).

### **Key US Companion Diagnostic Market Trends Highlighted**

The US Companion Diagnostic Market is experiencing significant growth driven by the increasing adoption of personalized medicine and advancements in genomics. Regulatory agencies, particularly the FDA, have been supportive of the development of companion diagnostics, which enhances the approval process of targeted therapies. This supportive regulatory environment is a crucial market driver as it encourages manufacturers to invest in developing innovative diagnostic tools. Furthermore, the rise in cancer prevalence and the growing demand for personalized treatment options are propelling the need for companion diagnostics, particularly in oncology.

There are also numerous opportunities to be explored within the US market. The increasing collaboration between diagnostic companies and pharmaceutical firms presents an avenue for developing novel companion diagnostics that can significantly improve patient outcomes. Additionally, the integration of artificial intelligence and machine learning into diagnostic processes can streamline the workflow and enhance accuracy, offering a promising area for growth. The trend toward increased precision in medical treatments aligns well with these technological advancements.

In recent times, there has been a notable shift towards the adoption of liquid biopsies, which have the potential to provide real-time insights into disease progression and treatment response.This trend is particularly relevant in cancer diagnostics as it enables non-invasive monitoring of tumor dynamics. Moreover, telemedicine and remote patient monitoring have gained traction, supporting the need for diagnostic solutions that can easily integrate with these technologies.

Overall, the US Companion Diagnostic Market is shaped by these trends, driven by regulatory support, a focus on personalized medicine, and advancements in technology, creating a dynamic and evolving landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Companion Diagnostic Market Drivers**

### **Rising Prevalence of Cancer in the US**

The increasing incidence of cancer in the US is one of the primary drivers for the US Companion Diagnostic Market Industry. According to the American Cancer Society, in 2021 alone, an estimated 1.898 million new cancer cases were diagnosed, with projections indicating that this number may increase by 26% by 2040. As precision medicine becomes an integral part of cancer treatment, the demand for companion diagnostics, which help identify the right treatment for the right patient, will continue to surge.

Organizations like Genomic Health and Foundation Medicine have been at the forefront of developing innovative companion diagnostics that are specifically designed to cater to various cancer types, thereby enhancing the treatment landscape. This ever-growing patient population requires more precise diagnostic tools, prompting an accelerated market growth for companion diagnostics. Moreover, supportive initiatives from the National Cancer Institute to bolster Research and Development in precision medicine are expected to further stimulate advancements in this sector.

### **Innovations in Genetic Testing Techniques**

Advancements in genetic testing technologies, including next-generation sequencing, are revolutionizing the landscape of diagnostics, specifically in the US Companion Diagnostic Market Industry. The ability to analyze a patient's genetic makeup leads to more tailored therapeutic strategies, particularly for complex diseases like cancer. As per the National Institutes of Health, the use of advanced genetic testing methods has surged by over 50% in recent years, indicating a marked shift towards personalized medicine.

Companies such as Illumina and Thermo Fisher Scientific are notable leaders in providing next-generation sequencing platforms, significantly enhancing the development of companion diagnostics that cater to targeted therapies. As regulatory agencies like the Food and Drug Administration continue to embrace innovative technologies, this trend is set to grow, ensuring a positive trajectory for the market.

### **Increasing Focus on Personalized Medicine**

The growing emphasis on personalized medicine is shaping the future of the US Companion Diagnostic Market Industry, as healthcare providers increasingly seek personalized treatment options for patients. Studies have shown that approximately 70% of all drugs can have variable responses based on genetic variation among individuals, showcasing the crucial role of companion diagnostics in matching patients to the appropriate therapies. Organizations like the American Society of Clinical Oncology advocate for precision medicine initiatives, which continue to receive increasing support from both governmental and private sectors, stimulating the demand for companion diagnostics that are essential for personalized approaches.

Furthermore, the push for regulatory frameworks designed to expedite the approval of these advanced diagnostics motivates further investments in innovative diagnostic solutions, thereby broadening their adoption across healthcare settings.

### **Regulatory Support for Companion Diagnostics**

Governmental regulatory bodies are increasingly supporting the development of companion diagnostics to enhance the quality of cancer care in the US, which acts as a catalyst for the US Companion Diagnostic Market Industry. The Food and Drug Administration has made significant strides in establishing guidelines specifically for companion diagnostics, streamlining the approval process and encouraging pharmaceutical companies to embrace these testing solutions.Reports suggest that in the last five years, the FDA has approved over 20 companion diagnostics, a substantial increase compared to previous years.

This trend not only motivates pharmaceutical companies to invest in R&D of companion diagnostics but also ensures that patients receive targeted therapies promptly, driving the market growth forward. The synergy between regulatory support and market needs is likely to bolster the adoption of companion diagnostics widely across the healthcare industry, further expanding patient access to cutting-edge therapeutic options.

## **US Companion Diagnostic Market Segment Insights**

### **Companion Diagnostic Market Product & Service Insights**

The US Companion Diagnostic Market within the Product and Service segment is a significant aspect of the healthcare landscape, particularly as it gears towards personalized medicine. This segment encompasses various critical components, including assays, kits, reagents, software, and services that facilitate the efficient identification of the right therapies for patients based on their individual genetic profiles. Assays play a crucial role by providing the necessary testing methodologies that allow for the reliable detection of biomarkers, which are vital for determining patient-specific treatment plans.

Kits and reagents support these assays by ensuring they are accessible and user-friendly while delivering accurate results in a timely manner, making them indispensable in clinical settings.

Software solutions within the Product and Service segment enhance laboratory workflows and improve data management and analysis, thus facilitating better decision-making in treatment pathways. Furthermore, the Services category provides essential support, including consultation and guidance on the best diagnostic practices, as well as the implementation of these advanced technologies in clinical environments. This tight integration among assays, kits, reagents, software, and services not only strengthens the functionality of diagnostics but also promotes a patient-centered approach in the US healthcare system.

The demand for these products and services is driven by various factors, including an increasing prevalence of chronic diseases, advancements in genomic technologies, and a growing emphasis on tailored therapies that promise better patient outcomes. Moreover, the regulatory landscape in the US is evolving, with health authorities actively encouraging the development and integration of companion diagnostics to align treatments with patient genetic profiles. This trend is likely to create a robust support system for the Product and Service segment, offering ample opportunities for innovation and expansion.

Despite the potential and momentum of this market segment, challenges such as reimbursement issues for diagnostic tests and the complexity of regulatory approvals remain pertinent. Nevertheless, the ongoing efforts to establish comprehensive guidelines and collaborative frameworks between diagnostic manufacturers and healthcare providers signify proactive measures to overcome these hurdles. As the US Companion Diagnostic Market continues to grow, a focus on enhancing the quality and accessibility of these essential products and services will be paramount in ensuring that patients receive the most effective and tailored therapeutic interventions.

The importance of this segment thus lies in its ability to influence treatment strategies through more precise diagnostics, ultimately leading to improved health outcomes for patients across the United States. The underlying market dynamics illustrate a forward-moving industry supporting both medical innovation and patient-centric care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Companion Diagnostic Market Technology Insights**

The Technology segment of the US Companion Diagnostic Market plays a vital role in advancing personalized medicine. This segment includes various techniques, such as Polymerase Chain Reaction, which is widely utilized for its accuracy in amplifying specific DNA sequences, making it crucial for genetic testing. Next-Generation Sequencing stands out due to its high throughput and ability to analyze multiple genes simultaneously, thereby enhancing patient-specific therapies. In Situ Hybridization is noteworthy for its application in visualizing specific nucleic acid sequences within fixed tissues, providing essential insights into cellular environments.

Immunohistochemistry remains a dominant method for determining protein expressions in various cancers, facilitating targeted treatment approaches. Lastly, other technologies contribute to innovation and diversification within the market, allowing for the integration of new methodologies into clinical applications. The continuous advancements and adoption of these technologies underline the critical role they play in shaping the landscape of the US Companion Diagnostic Market, ultimately impacting patient outcomes and treatment efficiency.

### **Companion Diagnostic Market Indication Insights**

The US Companion Diagnostic Market is a rapidly evolving field, primarily focused on improving patient outcomes through tailored therapies based on individual patient data. Within this market, indication segments such as Cancer, Neurological Diseases, Infectious Diseases, and Cardiovascular Diseases play a critical role, with significant implications for patient management. Cancer diagnostics dominate this segment due to the rising incidence of various cancers and the necessity for personalized treatment plans, which drive demand for precise biomarkers.

Neurological diseases have also gained attention owing to advancements in diagnostic technologies that help in early detection, crucial for conditions like Alzheimer's and Parkinson's disease. Infectious diseases have seen increased relevance, especially in light of global health challenges, emphasizing the need for rapid and accurate testing methods. Cardiovascular diseases remain a critical focus because they contribute to a high mortality rate, thus highlighting the need for effective diagnostic tools to guide treatment strategies.

The segmentation of the US Companion Diagnostic Market is shaped by these conditions, driving innovation and growth opportunities while addressing distinct healthcare challenges faced in the region.As the landscape continues to develop, ongoing Research and Development efforts are likely to lead to new opportunities across these segments, ensuring improved healthcare outcomes for patients in the US.

### **Companion Diagnostic Market End User Insights**

The End User segment of the US Companion Diagnostic Market plays a pivotal role in the broader landscape of personalized medicine. Pharmaceutical and Biopharmaceutical Companies are increasingly investing in companion diagnostics to enhance their drug development processes, ensuring that therapies are tailored to the right patient populations. This segment is crucial for driving innovation as these companies utilize companion diagnostics to identify biomarkers and improve patient outcomes. Contract Research Organizations are also integral to this market segment, providing necessary expertise and resources to facilitate clinical trials and validation processes.

Their ability to streamline research and development efforts allows for faster time to market for diagnostic products. Laboratories represent another key component, often acting as the frontline for testing and deploying companion diagnostics in clinical settings; their role in interpreting test results and providing actionable insights is critical in treatment decisions. The Others category encompasses various stakeholders, indicating the diverse ecosystem of entities contributing to the efficacy of companion diagnostics in the US.

Overall, the segmentation of the End User market reflects a robust framework that supports the ongoing growth and development of the US Companion Diagnostic Market, with each segment playing an essential role in augmenting patient care and advancing healthcare solutions.

## **US Companion Diagnostic Market Key Players and Competitive Insights**

The US Companion Diagnostic Market is characterized by a dynamic competitive landscape, which has evolved significantly due to rapid advancements in technology and the increasing emphasis on personalized medicine. Companion diagnostics are essential tools that enable clinicians to identify the most suitable therapies for patients based on their unique genetic profiles or other biomarkers. This market is heavily influenced by innovation, regulatory approvals, and collaborations between diagnostic companies and pharmaceutical firms. The competitive insights reflect an ongoing trend toward integrating diagnostic testing with targeted therapies, creating a synergy that benefits both patients and healthcare providers.

As the market expands, companies are focusing on developing novel diagnostics that complement existing therapies and improve patient outcomes, which is leading to an intensified competitive environment.

### **Key Players Analysis**

Illumina holds a strong position within the US Companion Diagnostic Market, renowned for its cutting-edge sequencing technologies that facilitate genomic analysis. The company’s prowess in next-generation sequencing (NGS) has established it as a leader in the field, providing robust solutions for precision medicine and oncology. Illumina’s offerings enable the identification of specific mutations or biomarkers that are crucial for selecting appropriate treatments, contributing to increased adoption among healthcare professionals.

The company continues to capitalize on the growing demand for personalized healthcare by expanding its partnerships with pharmaceutical companies and actively participating in clinical trials to validate its diagnostic tests. Its extensive market presence is bolstered by a reputation for reliability and accuracy, promoting its diagnostics as indispensable tools in crafting effective treatment plans tailored to individual patients.

Novartis is another significant player in the US Companion Diagnostic Market, integrating diagnostics with its pharmaceutical innovations to enhance therapeutic effectiveness. The company’s strategy includes the development of companion diagnostics alongside its targeted therapies, allowing for substance-specific drug interactions that optimize treatment options for various conditions, particularly in oncology. Key products within its portfolio focus on aiding in the selection of treatments that correspond with specific genetic profiles.

Novartis has also pursued strategic mergers and acquisitions to bolster its capabilities in the diagnostics domain and improve its market reach in the US. This commitment not only strengthens its position in the market but also allows for a more comprehensive approach to patient care, ensuring that the therapies it develops are used in conjunction with the appropriate diagnostic tests. By aligning its product development with the latest advancements in genetics, Novartis remains a formidable contender in shaping the future of personalized medicine in the United States.

### **Key Companies in the US Companion Diagnostic Market Include**

## **US Companion Diagnostic Market Industry Developments**

In recent developments, the US Companion Diagnostic Market has witnessed significant advancements, particularly among key players such as Illumina, Novartis, and Roche. For instance, in April 2023, Illumina announced a partnership with Merck to develop companion diagnostics for immune-oncology therapies, expanding their genomic sequencing capabilities. In June 2023, BioRad Laboratories launched a new product line aimed explicitly at enhancing the accuracy of companion diagnostics in oncology, reflecting the growing demand for personalized medicine. Merger and acquisition activity has also been notable; in May 2023, Thermo Fisher Scientific acquired MGI Tech, enhancing its genetic sequencing and diagnostic offerings.

The US market continues to grow, driven by increased adoption of targeted therapies and advancements in precision medicine. Companies such as Myriad Genetics and Foundation Medicine are actively enhancing their product portfolios to meet healthcare providers' needs for accurate diagnostics. Growth trends in the market indicate a strong valuation increase for these companies, attributed to ongoing investments in Research and Development, technology innovations, and expansions in regulatory approvals for companion diagnostic tests, highlighting the dynamic nature of this sector in the US healthcare landscape.

## **US Companion Diagnostic Market Segmentation Insights**

### **Companion Diagnostic Market Product & Service Outlook**

### **Companion Diagnostic Market Technology Outlook**

### **Companion Diagnostic Market Indication Outlook**

### **Companion Diagnostic Market End User Outlook**

## Market Drivers

### Advancements in Genomic Technologies

Technological innovations in genomic sequencing and molecular diagnostics are significantly influencing the companion diagnostic market. The advent of next-generation sequencing (NGS) has enabled more precise identification of genetic mutations, which is crucial for the development of targeted therapies. In the US, the market for genomic testing is projected to reach approximately $25 billion by 2026, indicating a robust growth trajectory. This growth is likely to enhance the capabilities of the companion diagnostic market, as more sophisticated tests become available, allowing for better patient stratification and treatment personalization.

### Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as cancer, cardiovascular disorders, and diabetes is a primary driver for the companion diagnostic market. As these conditions become more prevalent, the demand for personalized medicine rises, necessitating the use of companion diagnostics to tailor treatments to individual patients. In the US, it is estimated that nearly 1.9 million new cancer cases are diagnosed annually, highlighting the need for effective diagnostic tools. The companion diagnostic market is thus positioned to grow, as healthcare providers seek to improve patient outcomes through targeted therapies that are informed by diagnostic testing.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine is reshaping the landscape of the companion diagnostic market. Patients and healthcare providers are increasingly recognizing the value of tailored treatment approaches that consider individual genetic profiles. This trend is supported by a growing body of evidence demonstrating improved treatment efficacy and reduced adverse effects. In the US, the personalized medicine market is expected to exceed $2 trillion by 2025, which could significantly bolster the companion diagnostic market as more healthcare systems adopt these strategies to enhance patient care.

### Regulatory Support for Companion Diagnostics

Regulatory bodies in the US are providing enhanced support for the development and approval of companion diagnostics, which is a vital driver for the market. Initiatives aimed at streamlining the regulatory process for these diagnostics are encouraging innovation and expediting time-to-market for new tests. The FDA has established specific pathways for the approval of companion diagnostics, which may lead to a more favorable environment for companies operating in the companion diagnostic market. This regulatory support is likely to facilitate the introduction of new diagnostic tools that align with the latest therapeutic advancements.

### Increased Investment in Research and Development

Investment in research and development (R&D) within the pharmaceutical and biotechnology sectors is a critical driver for the companion diagnostic market. Companies are increasingly allocating resources to develop innovative diagnostic solutions that can complement new therapies. In the US, R&D spending in the life sciences sector has seen a steady increase, with estimates suggesting that it could reach $200 billion by 2025. This influx of funding is likely to foster advancements in the companion diagnostic market, leading to the introduction of novel tests that align with emerging therapeutic options.

## Future Outlook

The [Companion Diagnostic Market](https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077) is projected to grow at a 6.5% CAGR from 2025 to 2035, driven by advancements in personalized medicine, regulatory support, and increasing prevalence of chronic diseases.

**New opportunities:**

- Development of AI-driven diagnostic algorithms for enhanced accuracy. Expansion of partnerships with pharmaceutical companies for co-development. Investment in telehealth platforms for remote diagnostic services.

By 2035, the companion diagnostic market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product & Service: Assays, Kits, & Reagents (Largest) vs. Software & Services (Fastest-Growing)

In the companion diagnostic market, Assays, Kits, & Reagents constitute the largest segment, holding a substantial market share compared to Software & Services. Assays, Kits, & Reagents are critical for the detection and monitoring of diseases, which has solidified their dominance within the market. Conversely, while Software & Services occupy a smaller market share, they are quickly gaining traction due to the increasing demand for digital solutions in healthcare. Growth trends indicate a robust expansion for both segments, driven by advancements in technology and an increasing emphasis on personalized medicine. The rising prevalence of chronic diseases pushes healthcare providers to adopt companion diagnostics, particularly assays for tailored treatment strategies. Additionally, the surge in software solutions that enhance diagnostics processes and analyze patient data underscores the potential for Software & Services to emerge as a leading component in the market.

Assays, Kits, & Reagents (Dominant) vs. Software & Services (Emerging)

Assays, Kits, & Reagents represent the dominant force within the US companion diagnostic market, characterized by their crucial role in the precise identification of biomarkers for targeted therapies. Their widespread use in clinical settings showcases the reliability and efficiency they provide healthcare professionals. On the other hand, Software & Services are emerging as a transformative component of the market, leveraging technology to streamline diagnostic processes and improve patient outcomes. The integration of advanced data analytics and artificial intelligence in Software & Services is propelling growth, allowing for more personalized and accurate diagnostics solutions. As the market evolves, both segments are essential, with Assays, Kits, & Reagents continuing to lead while Software & Services expand their influence.

### By Technology: PCR (Largest) vs. NGS (Fastest-Growing)

The US companion diagnostic market exhibits a diverse range of technologies, with Polymerase Chain Reaction (PCR) holding the largest market share due to its established applications and widespread acceptance in clinical settings. Next-Generation Sequencing (NGS) is emerging swiftly, capturing the interest of stakeholders through its comprehensive genomic profiling capabilities, leading to increased adoption alongside PCR. In contrast, In Situ Hybridization (ISH) and Immunohistochemistry (IHC) continue to maintain a steady presence, while other methods contribute modestly to the overall market dynamics. Growth trends indicate a robust expansion trajectory for NGS, largely driven by technological advancements and decreasing costs. The increasing incidence of cancer and the need for personalized medicine are key catalysts propelling the demand for companion diagnostics. PCR remains crucial due to its reliability in specific applications, while the growing focus on integrated diagnostic solutions places NGS at the forefront of the market evolution, suggesting a shift towards more sophisticated testing methodologies.

Technology: PCR (Dominant) vs. NGS (Emerging)

PCR is recognized for its role in diagnostics, offering rapid results and high sensitivity, making it a preferred choice in various clinical applications. Its dominance is attributed to its proven track record and extensive use in detecting specific genetic mutations crucial for patient treatment decisions. On the other hand, NGS is carving a niche as an emerging technology that provides a deeper understanding of genomic data, which is essential for comprehensive cancer care. The ability of NGS to analyze multiple genes simultaneously positions it as a revolutionary tool that appeals to healthcare providers aiming for personalized and targeted therapy options, marking a significant shift in how diagnostics are approached within the market.

### By Indication: Cancer (Largest) vs. Neurological Diseases (Fastest-Growing)

In the US companion diagnostic market, Cancer emerges as the largest segment, dominating market share due to the high prevalence and complexity of various cancer types. Neurological Diseases and Infectious Diseases follow, though they hold smaller shares, pointing to focused investment and research in targeted therapies. Cardiovascular Diseases and Others also contribute to the overall market, yet their impact remains comparatively limited at this time. The growth trends within the US companion diagnostic market reveal a substantial increase in the demand for personalized medicine, particularly in Cancer and Neurological Diseases. The rapid advancement in genomic and molecular technologies propels the growth trajectory for companion diagnostics. Increasing incidences of chronic diseases also stimulate the adoption of diagnostics that can tailor treatments for improved patient outcomes, especially in the emerging fields like Neurological Diseases.

Cancer (Dominant) vs. Neurological Diseases (Emerging)

In the US companion diagnostic market, Cancer diagnostics play a dominant role, primarily driven by a significant rise in personalized treatment strategies that cater to individual tumor profiles. This segment benefits from advancements in biomarker identification and precision medicine, allowing for more effective treatment protocols. In contrast, Neurological Diseases represent an emerging segment characterized by innovative diagnostic tools aimed at managing complex conditions such as Alzheimer’s or multiple sclerosis. The growth of this segment is fueled by increased research spending and heightened awareness of neurological health issues, highlighting its importance in comprehensive healthcare solutions.

### By End User: Pharmaceutical & Biopharmaceutical Companies (Largest) vs. Contract Research Organizations (Fastest-Growing)

In the US companion diagnostic market, the segment values show a distinct distribution in market share. Pharmaceutical and biopharmaceutical companies dominate this market, leveraging their extensive resources and established relationships with healthcare providers. In contrast, contract research organizations are gaining traction, appealing to smaller firms looking for specialized services. Growth trends indicate that contract research organizations are emerging as a significant player, driven by an increase in personalized medicine. The rising demand for companion diagnostics tailored to specific therapies is accelerating investments in this segment, enhancing its growth potential. The integration of advanced technologies and collaborative studies are key drivers propelling forward this competitive landscape.

Pharmaceutical & Biopharmaceutical Companies (Dominant) vs. Contract Research Organizations (Emerging)

Pharmaceutical and biopharmaceutical companies stand as the dominant force in the US companion diagnostic market due to their substantial investment in research and development, coupled with an extensive pipeline of targeted therapies. Their robust infrastructure supports effective collaboration with diagnostic manufacturers. Conversely, contract research organizations are seen as an emerging force, offering flexibility and specialized expertise, which attracts smaller biotech firms seeking innovative solutions in companion diagnostics. This segment benefits from the growing trend of partnerships between academic institutions and research organizations, fueling a rise in novel approaches to personalized therapy.

## Competitive Benchmarking

The companion diagnostic market is characterized by a dynamic competitive landscape, driven by advancements in personalized medicine and the increasing demand for targeted therapies. Key players such as Roche (CH), Thermo Fisher Scientific (US), and Illumina (US) are at the forefront, leveraging their extensive research capabilities and technological innovations to enhance their market positions. Roche (CH) focuses on integrating diagnostics with therapeutic solutions, thereby streamlining patient management. Meanwhile, Thermo Fisher Scientific (US) emphasizes its commitment to innovation through strategic partnerships and acquisitions, which bolster its product offerings and market reach. Illumina (US) continues to lead in genomic sequencing technologies, positioning itself as a critical player in the development of companion diagnostics that align with precision medicine initiatives. The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market presence. Localizing manufacturing and optimizing supply chains are prevalent strategies aimed at reducing costs and improving responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies shapes a landscape where innovation and strategic collaborations are paramount. In October 2025, Roche (CH) announced a collaboration with a leading biotechnology firm to develop a novel companion diagnostic for a new oncology therapy. This partnership is expected to enhance Roche's capabilities in delivering personalized treatment options, thereby reinforcing its competitive edge in the oncology segment. The strategic importance of this collaboration lies in its potential to accelerate the development timeline and improve patient outcomes through tailored therapies. In September 2025, Thermo Fisher Scientific (US) launched a new platform designed to streamline the development of companion diagnostics. This platform integrates advanced analytics and AI capabilities, allowing for more efficient data processing and interpretation. The introduction of this technology signifies a shift towards digital transformation in the companion diagnostic space, enabling faster and more accurate diagnostic solutions that align with evolving healthcare needs. In August 2025, Illumina (US) expanded its partnership with a prominent pharmaceutical company to enhance the integration of genomic data into clinical decision-making processes. This strategic move is indicative of Illumina's commitment to advancing precision medicine and underscores the growing importance of genomic insights in companion diagnostics. By fostering such collaborations, Illumina positions itself as a leader in the integration of genomic technologies into routine clinical practice. As of November 2025, current trends in the companion diagnostic market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing product offerings. Looking ahead, the evolution of competitive differentiation is likely to pivot from traditional price-based competition towards a focus on technological advancements, innovation, and supply chain reliability. This shift underscores the necessity for companies to adapt and innovate continuously to maintain their competitive positions in an ever-evolving market.

## Recent News & Developments

In recent developments, the US Companion Diagnostic Market has witnessed significant advancements, particularly among key players such as Illumina, Novartis, and Roche. For instance, in April 2023, Illumina announced a partnership with Merck to develop companion diagnostics for immune-oncology therapies, expanding their genomic sequencing capabilities. In June 2023, BioRad Laboratories launched a new product line aimed explicitly at enhancing the accuracy of companion diagnostics in oncology, reflecting the growing demand for personalized medicine. Merger and acquisition activity has also been notable; in May 2023, Thermo Fisher Scientific acquired MGI Tech, enhancing its genetic sequencing and diagnostic offerings.

The US market continues to grow, driven by increased adoption of targeted therapies and advancements in precision medicine. Companies such as Myriad Genetics and Foundation Medicine are actively enhancing their product portfolios to meet healthcare providers' needs for accurate diagnostics. Growth trends in the market indicate a strong valuation increase for these companies, attributed to ongoing investments in Research and Development, technology innovations, and expansions in regulatory approvals for companion diagnostic tests, highlighting the dynamic nature of this sector in the US healthcare landscape.

## Report Scope

| MARKET SIZE 2024 | 1500.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1597.5(USD Million) |
| MARKET SIZE 2035 | 3000.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Illumina (US), Qiagen (DE), Myriad Genetics (US), Hologic (US), BioMérieux (FR) |
| Segments Covered | Product & Service, Technology, Indication, End User |
| Key Market Opportunities | Integration of artificial intelligence in companion diagnostic market enhances personalized medicine approaches. |
| Key Market Dynamics | Rising regulatory scrutiny and technological advancements drive innovation in the companion diagnostic market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the projected market valuation for the US companion diagnostic market in 2035?**
A: The projected market valuation for the US companion diagnostic market in 2035 is $3000.0 Million.

**Q: What was the market valuation for the US companion diagnostic market in 2024?**
A: The market valuation for the US companion diagnostic market in 2024 was $1500.0 Million.

**Q: What is the expected CAGR for the US companion diagnostic market from 2025 to 2035?**
A: The expected CAGR for the US companion diagnostic market during the forecast period 2025 - 2035 is 6.5%.

**Q: Which companies are considered key players in the US companion diagnostic market?**
A: Key players in the US companion diagnostic market include Roche, Thermo Fisher Scientific, Abbott, Agilent Technologies, Illumina, Qiagen, Myriad Genetics, Hologic, and BioMérieux.

**Q: What are the main product segments in the US companion diagnostic market?**
A: The main product segments in the US companion diagnostic market include Assays, Kits, & Reagents, and Software & Services, with valuations of $900.0 Million to $1800.0 Million and $600.0 Million to $1200.0 Million, respectively.

**Q: What technologies are driving the US companion diagnostic market?**
A: Technologies driving the US companion diagnostic market include Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), and Immunohistochemistry (IHC), with valuations ranging from $150.0 Million to $900.0 Million.

**Q: What indications are primarily targeted by the US companion diagnostic market?**
A: The primary indications targeted by the US companion diagnostic market include Cancer, Neurological Diseases, Infectious Diseases, and Cardiovascular Diseases, with valuations from $200.0 Million to $1200.0 Million.

**Q: Who are the main end users of companion diagnostics in the US market?**
A: Main end users of companion diagnostics in the US market include Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, and Laboratories, with valuations between $200.0 Million and $1200.0 Million.

**Q: How does the US companion diagnostic market compare to its projected growth by 2035?**
A: The US companion diagnostic market is expected to grow from $1500.0 Million in 2024 to $3000.0 Million by 2035, indicating a robust growth trajectory.

**Q: What role do pharmaceutical companies play in the US companion diagnostic market?**
A: Pharmaceutical & Biopharmaceutical Companies are crucial in the US companion diagnostic market, accounting for a valuation between $600.0 Million and $1200.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-companion-diagnostic-market-14649*